<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296138</url>
  </required_header>
  <id_info>
    <org_study_id>1237.19</org_study_id>
    <secondary_id>2014-002275-28</secondary_id>
    <nct_id>NCT02296138</nct_id>
  </id_info>
  <brief_title>Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.</brief_title>
  <official_title>A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD. [DYNAGITO]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed
      dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on
      moderate to severe COPD exacerbation in patients with severe to very severe COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2015</start_date>
  <completion_date type="Actual">March 29, 2017</completion_date>
  <primary_completion_date type="Actual">March 8, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualised Rate of Moderate to Severe COPD Exacerbations During the Actual Treatment Period.</measure>
    <time_frame>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</time_frame>
    <description>Annualised rate of moderate to severe COPD exacerbations during the actual treatment period was calculated per treatment per patient−year. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. Least Squares Means are actually exponentiated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One Moderate to Severe COPD Exacerbation During the Actual Treatment Period.</measure>
    <time_frame>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</time_frame>
    <description>Key secondary endpoint: Number of patients with at least one moderate to severe COPD exacerbation during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with at least one moderate to severe COPD exacerbation is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualised Rate of Exacerbations Leading to Hospitalisation During the Actual Treatment Period.</measure>
    <time_frame>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</time_frame>
    <description>Annualised rate of exacerbations leading to hospitalisation during the actual treatment period was calculated per treatment per patient−year. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One COPD Exacerbation Leading to Hospitalisation During the Actual Treatment Period.</measure>
    <time_frame>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</time_frame>
    <description>Number of patients with at least one COPD exacerbation leading to hospitalisation during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with at least one moderate to severe COPD exacerbation leading to hospitalisation is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With All-cause Mortality Occurring During the Actual Treatment Period.</measure>
    <time_frame>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</time_frame>
    <description>Number of patients with all-cause mortality occurring during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with all-cause mortality is presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7903</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>tiotropium + olodaterol high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily 2 puffs solution for inhalation Respimat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily 2 puffs solution for inhalation Respimat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olodaterol</intervention_name>
    <description>fixed dose combination</description>
    <arm_group_label>tiotropium + olodaterol high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>fixed dose combination</description>
    <arm_group_label>tiotropium + olodaterol high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <arm_group_label>tiotropium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female patients, 40 years of age or older.

          -  Diagnosis of COPD with a documented post-bronchodilator Forced expiratory volume in
             one second (FEV1)&lt; 60% of predicted normal and a post-bronchodilator FEV1/ forced
             vital capacity (FVC) &lt;70% at Visit 1

          -  Documented history of at least one moderate to severe COPD exacerbation in the
             previous 12 months requiring treatment with systemic corticosteroids and/or
             antibiotics and/or related hospitalization.

          -  Symptomatically stable as defined by: no evidence of COPD exacerbation requiring use
             of either antibiotics and/or steroids 4 weeks prior to visit 1 and no evidence of
             change in their usual COPD medication 4 weeks prior to visit 1.

          -  Current or ex-smokers with a smoking history of more than 10 pack years.

        Exclusion criteria:

          -  Significant disease other than COPD.

          -  Clinically relevant abnormal baseline haematology, blood chemistry or creatinine &gt; x2
             ULN will be excluded regardless of clinical condition. ( A repeat laboratory
             evaluation can be conducted if deemed necessary by the investigator.)

          -  Current documented diagnosis of asthma. For patients with allergic rhinitis or atopy,
             source documentation is required to verify that the patient does not have asthma

          -  A diagnosis of thyrotoxicosis

          -  A history of myocardial infarction within 6 months of screening visit.

          -  Life-threatening cardiac arrhythmia.

          -  Known active tuberculosis.

          -  Any malignancy unless free of disease for at least 5 years (patients with treated
             basal cell carcinoma or squamous cell skin cancers are allowed).

          -  A history of cystic fibrosis.

          -  Clinically relevant bronchiectasis.

          -  Patients with severe emphysema requiring endobronchial interventions within 6 months
             prior to screening

          -  A history of significant alcohol or drug abuse in the opinion of the investigator.

          -  Patients who have undergone thoracotomy with pulmonary resection

          -  Patients being treated with oral or patch ß-adrenergics.

          -  Patients being treated with oral corticosteroid medication at unstable doses

          -  Patients being treated with antibiotics for any reasons within 4 weeks of screening
             visit

          -  Patients being treated with PDE4 inhibitors within 3 months of screening visit

          -  Patients who have taken an investigational drug within one month or six half-lives

          -  Pregnant or nursing women.

          -  Women of childbearing potential not using a highly effective method of birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1237.19.10039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Flagstaff</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10157 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10142 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10133 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10093 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10000 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10135 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10145 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10130 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>O'Fallon</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10122 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Mitchell</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10095 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Opelousas</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10139 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10138 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10075 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10096 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10084 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10097 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10094 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10137 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Larchmont</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10143 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calabash</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10098 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10131 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10154 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10087 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10127 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10121 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10148 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10147 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10146 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10129 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10140 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oaks</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10136 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10126 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10086 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10128 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10099 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indian Land</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10144 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10153 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10091 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10076 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10089 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10120 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10092 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.10016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bahía Blanca</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berazategui</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quilmes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Isidro</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.54001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.61012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.61011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.61008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.61010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.61006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daw Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kent Town</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.61007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.61013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.61003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.61009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.61004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.43006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Feldbach</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leoben</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ryazan</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.43005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.32007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.32006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gilly</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jambes</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lebbeke</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zichem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.55007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.55013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Botucatu</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.55011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goiania</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.55002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.55006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.55010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.55012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.55014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santo Andre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.55005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.55008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.55001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.55009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vitoria</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Troyan</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vidin</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maple Ridge</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint John¿s</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corunna</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Courtice</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grimsby</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Point Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St-Charles-Borromée</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoriaville</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.20014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.53004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quillota</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.53003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Miguel</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.53002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.57002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.57004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.57005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.57003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.57006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beroun</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cesky Krumlov</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krnov</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liberec</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melnik</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague 8</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Varnsdorf</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.45007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.45006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Holstebro</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.45005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolding</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.45008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vaerløse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ålborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35805 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>MARSEILLE Cedex 08</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes Cedex 01</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nîmes cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rennes Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Laurent du Var</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Pierre - La Réunion</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>TOURS Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.33010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vieux Condé</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ahlen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Wörishofen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bergisch Gladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49076 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düren</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fürstenwalde</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gütersloh</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halle/Saale</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Höchstädt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Landsberg am Lech</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paderborn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Peine</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Radebeul</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rheine</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rüdersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Solingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Teuchern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wardenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesloch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.49023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.30003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.30007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.30008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.30004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.30002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nafplio</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.30005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Serres</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.30006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.50201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.50202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.50203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.50204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.50205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.85201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.85202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.85203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edeleny</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Farkasgyepu</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Godollo</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hajdunanas</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kapuvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Komarom</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szazhalombatta</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ahmadabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gurgaon</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Karamsad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ludhiana</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mysore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mysore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Panjim</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vellore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.91028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vishakhapatnam</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 24</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wilton</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cittadella (PD)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pordenone</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Pietro Vernotico (BR)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.39019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Scafati (SA)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aichi, Komaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aichi, Obu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aichi, Seto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiba, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiba, Kamogawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukui, Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Kitakyushu-city</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Koga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Yanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Yukuhashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukushima, Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gifu, Mizunami</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gifu, Ogaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gunma, Fujioka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gunma, Maebashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gunma, Takasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hiroshima, Fukuyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hiroshima, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hiroshima, Kure</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hiroshima, Kure</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Asahikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Chitose</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Hakodate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Hakodate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Obihiro</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Obihiro</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Otaru</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Tomakomai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81090 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyogo, Himeji</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81093 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyogo, Himeji</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81091 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyogo, Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81092 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyogo, Nishinomiya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ibaraki, Hitachinaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81129 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ibaraki, Inashiki-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ibaraki, Naka-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ishikawa, Kanazawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iwate, Morioka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kagawa, Sakaide</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kagawa, Takamatsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kagawa, Takamatsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kagoshima, Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Isehara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Sagamihara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Sagamihara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kochi, Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81130 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kochi, Nankoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81076 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mie, Matsusaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miyagi, Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miyagi, Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miyagi, Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miyagi, Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagano, Matsumoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagano, Matumoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagasaki, Isahaya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81095 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nara, Ikoma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Niigata, Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Niigata, Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Niigata, Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81100 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okayama, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81125 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Urasoe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81120 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Uruma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81089 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Ikeda</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Kishiwada</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81078 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osakasayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81079 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81086 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81088 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Sakai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Takatsuki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Toyonaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81087 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Yao</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Koshigaya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81128 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shiga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81098 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimane, Izumo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81099 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimane, Izumo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shizuoka, Hamamatsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shizuoka, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tochigi, Shimotsuke</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81075 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chiyoda-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Hachioji</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Itabashi-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Itabashi-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Koto-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Meguro-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Minato-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Shinagawa-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Tachikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Toshima-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81122 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo,</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81126 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81097 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wakayama, Hidaka-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81096 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wakayama, Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yamagata, Yonezawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yamagata,</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yamaguchi, Iwakuni</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yamaguchi, Ube</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.81062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yamanashi, Kofu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.82009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.82010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.37103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.37101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.37105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.37106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.37104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tukums</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.37102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.37002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.37003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.37004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.37001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.60006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kota Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.60002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.60004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Terengganu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.60001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuching</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.52006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.52007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.52005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>León</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.52003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>México</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.52004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tijuana</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>EDE</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sittard - Geleen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zutphen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.64003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Auckland, New Zealand</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.64004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Christchurch Central</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.64002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.64007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.64008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.64001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenlane East Auckland NZ</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.64005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.64009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arendal</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.47008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hønefoss</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.47006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kløfta</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.47007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lierskogen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.47004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.47005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Skedsmokorset</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.63007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angeles City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cebu City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.63003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dasmarinas</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.63008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Davao City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.63006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iloilo</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.63005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.63002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chojnice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Libiaz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ostow Wielkopolski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ostroda</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Piaseczno</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Skierniewice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Swidnik</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tarnobrzeg</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wolomin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zawadzkie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.48012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zgierz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almada</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Braga</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guimarães</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.35006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.40007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bragadiru</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.40003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.40004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.40005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.40008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.40002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.40006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gatchina</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lomonosov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Penza</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pskov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rosto-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ulyanovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.70036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sombor</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sremska Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.65001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.65002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Humenne</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poprad</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spisska Nova Ves</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.42105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vrable</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Golnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pohorje</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Topolsica</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amanzimtoti</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.27007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.27009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.27011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morningside, Sandton</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.27010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parow</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.27004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.27008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aranjuez</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barakaldo (Bilbao)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centelles</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Granollers (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet Llobregat (bcn)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liencres (Pielagos)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mérida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pozuelo de Alarcón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vic</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilanova i la Geltrú</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.46008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Härnösand</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Höllviken</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rättvik</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.46007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.41004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ascona</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.41002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.41001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liestal</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.88012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.88010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.88011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.88009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.88004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.88007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.88001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.88005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.88008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.88013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.66008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dusit</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.66005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hat Yai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.66003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maerim</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.66001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muang</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.66002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muang</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.66007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Patumwan</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.66004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rajathevee</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denizli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.90000 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.38008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.44008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bedford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bradford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chertsey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.44004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Doncaster</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Shields</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.84003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ha Noi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.84001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.19.84002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Ecuador</country>
    <country>El Salvador</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <results_first_submitted>March 7, 2018</results_first_submitted>
  <results_first_submitted_qc>May 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2018</results_first_posted>
  <last_update_submitted>May 31, 2018</last_update_submitted>
  <last_update_submitted_qc>May 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02296138/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 15, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02296138/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared with tiotropium on Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with severe to very severe COPD.</recruitment_details>
      <pre_assignment_details>Following informed consent, the patient was entered into a maximum 7-day screening period to confirm the patient’s eligibility. At Visit 2, after a successful review of the inclusion and exclusion criteria, the patient was randomly allocated in equal ratio to receive once daily trial treatment and then entered the 360 days treatment phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tiotropium 5 Microgram (μg)</title>
          <description>Patient received 5 μg Tiotropium inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium (5 μg) + Olodaterol (5 μg)</title>
          <description>Patient received 5 μg Tiotropium + 5 μg Olodaterol fixed-dose combination (FDC) inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3952"/>
                <participants group_id="P2" count="3951"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="3941"/>
                <participants group_id="P2" count="3939"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3291"/>
                <participants group_id="P2" count="3451"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="661"/>
                <participants group_id="P2" count="500"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="348"/>
                <participants group_id="P2" count="259"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
                <participants group_id="P2" count="131"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patients with data irregularities</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): This patient set includes all randomised patients who were documented to have taken at least 1 dose of trial medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Tiotropium 5 Microgram (μg)</title>
          <description>Patient received 5 μg Tiotropium inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium (5 μg) + Olodaterol (5 μg)</title>
          <description>Patient received 5 μg Tiotropium + 5 μg Olodaterol fixed-dose combination (FDC) inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3941"/>
            <count group_id="B2" value="3939"/>
            <count group_id="B3" value="7880"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at the time of signing informed consent form is presented.</description>
          <population>Treated Set</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="8.5"/>
                    <measurement group_id="B2" value="66.5" spread="8.4"/>
                    <measurement group_id="B3" value="66.4" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Number of subjects is categorized as Male or Female.</description>
          <population>Treated Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1100"/>
                    <measurement group_id="B2" value="1154"/>
                    <measurement group_id="B3" value="2254"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2841"/>
                    <measurement group_id="B2" value="2785"/>
                    <measurement group_id="B3" value="5626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Ethnicity was not captured in this trial</description>
          <population>Treated Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="607"/>
                    <measurement group_id="B2" value="557"/>
                    <measurement group_id="B3" value="1164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3113"/>
                    <measurement group_id="B2" value="3134"/>
                    <measurement group_id="B3" value="6247"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annualised Rate of Moderate to Severe COPD Exacerbations During the Actual Treatment Period.</title>
        <description>Annualised rate of moderate to severe COPD exacerbations during the actual treatment period was calculated per treatment per patient−year. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. Least Squares Means are actually exponentiated.</description>
        <time_frame>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</time_frame>
        <population>Treated set (TS) -This patient set includes all randomised patients who were documented to have taken at least 1 dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 Microgram (μg)</title>
            <description>Patient received 5 μg Tiotropium inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (5 μg) + Olodaterol (5 μg)</title>
            <description>Patient received 5 μg Tiotropium + 5 μg Olodaterol fixed-dose combination (FDC) inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
          </group>
        </group_list>
        <measure>
          <title>Annualised Rate of Moderate to Severe COPD Exacerbations During the Actual Treatment Period.</title>
          <description>Annualised rate of moderate to severe COPD exacerbations during the actual treatment period was calculated per treatment per patient−year. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. Least Squares Means are actually exponentiated.</description>
          <population>Treated set (TS) -This patient set includes all randomised patients who were documented to have taken at least 1 dose of trial medication.</population>
          <units>Rate per patient−year</units>
          <param>Least Squares Mean</param>
          <dispersion>99% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3941"/>
                <count group_id="O2" value="3939"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.90" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.84" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Annualised rate of moderate to severe COPD exacerbation was analysed using a negative binomial model including the fixed, categorical effect of treatment as well as the logarithm of the treatment exposure as an offset.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis testing strategy ensures that the overall type I error is protected at 2-sided 0.01 level.</non_inferiority_desc>
            <p_value>0.0498</p_value>
            <method>Negative binomial model</method>
            <param_type>Ratio of rates vs. Tiotropium 5 μg</param_type>
            <param_value>0.93</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Ratio of events Tiotropium (5 μg) + Olodaterol (5 μg) versus Tiotropium (5 μg) is provided.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Model was based on SPARK/FLAME- Covariates: Smoking status, baseline inhaled corticosteroid, Global Initiative on Chronic Obstructive Lung Disease stage, region, COPD Assessment Test score (replacing baseline symptom score), exacerbations treated with antibiotics/steroids history in previous year (replacing 1-year history of exacerbations)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>Negative binomial model</method>
            <param_type>Ratio of rates</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>Ratio of rates Tiotropium (5 μg) versus Tiotropium (5 μg) + Olodaterol (5 μg) is provided.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Model was based on HERMES- Covariates: age, sex, smoking status, baseline Long-acting Beta-agonist/inhaled corticosteroid, region and percent predicted post-bronchodilator Forced Expiratory Volume in One Second</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0080</p_value>
            <method>Negative binomial model</method>
            <param_type>Ratio of rates</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Ratio of rates Tiotropium (5 μg) versus Tiotropium (5 μg) + Olodaterol (5 μg) is provided.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Model was based on TRINITY/TRILOGY- Covariates: Treatment, region, severity of airflow limitation, and smoking status as effects, and exacerbations treated with antibiotics/steroids in previous year.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Negative binomial model</method>
            <param_type>Ratio of rates</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>Ratio of rates Tiotropium (5 μg) versus Tiotropium (5 μg) + Olodaterol (5 μg) is provided.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One Moderate to Severe COPD Exacerbation During the Actual Treatment Period.</title>
        <description>Key secondary endpoint: Number of patients with at least one moderate to severe COPD exacerbation during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with at least one moderate to severe COPD exacerbation is presented.</description>
        <time_frame>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</time_frame>
        <population>Treated set (TS) -This patient set includes all randomised patients who were documented to have taken at least 1 dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 Microgram (μg)</title>
            <description>Patient received 5 μg Tiotropium inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (5 μg) + Olodaterol (5 μg)</title>
            <description>Patient received 5 μg Tiotropium + 5 μg Olodaterol fixed-dose combination (FDC) inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One Moderate to Severe COPD Exacerbation During the Actual Treatment Period.</title>
          <description>Key secondary endpoint: Number of patients with at least one moderate to severe COPD exacerbation during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with at least one moderate to severe COPD exacerbation is presented.</description>
          <population>Treated set (TS) -This patient set includes all randomised patients who were documented to have taken at least 1 dose of trial medication.</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3941"/>
                <count group_id="O2" value="3939"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1777"/>
                    <measurement group_id="O2" value="1746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cox’s proportional hazard model was used to estimate the hazard ratio and the corresponding Confidence Interval. A log-rank test was used to obtain the p-value</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>This hypothesis testing strategy ensures that the overall type I error is protected at 2-sided 0.01 level.</non_inferiority_desc>
            <p_value>0.1188</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>Tiotropium (5 μg) + Olodaterol (5 μg) versus Tiotropium (5 μg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualised Rate of Exacerbations Leading to Hospitalisation During the Actual Treatment Period.</title>
        <description>Annualised rate of exacerbations leading to hospitalisation during the actual treatment period was calculated per treatment per patient−year. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication.</description>
        <time_frame>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</time_frame>
        <population>Treated set (TS) -This patient set includes all randomised patients who were documented to have taken at least 1 dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 Microgram (μg)</title>
            <description>Patient received 5 μg Tiotropium inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (5 μg) + Olodaterol (5 μg)</title>
            <description>Patient received 5 μg Tiotropium + 5 μg Olodaterol fixed-dose combination (FDC) inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
          </group>
        </group_list>
        <measure>
          <title>Annualised Rate of Exacerbations Leading to Hospitalisation During the Actual Treatment Period.</title>
          <description>Annualised rate of exacerbations leading to hospitalisation during the actual treatment period was calculated per treatment per patient−year. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication.</description>
          <population>Treated set (TS) -This patient set includes all randomised patients who were documented to have taken at least 1 dose of trial medication.</population>
          <units>Rate per patient−year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3941"/>
                <count group_id="O2" value="3939"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.18" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.16" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Annualised rate of exacerbations leading to hospitalization was analysed using a negative binomial model including the fixed, categorical effect of treatment as well as the logarithm of the treatment exposure as an offset.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1265</p_value>
            <method>Negative binomial model</method>
            <param_type>Ratio of events vs. Tiotropium 5 μg</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>Ratio of events Tiotropium (5 μg) + Olodaterol (5 μg) versus Tiotropium (5 μg) is provided.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One COPD Exacerbation Leading to Hospitalisation During the Actual Treatment Period.</title>
        <description>Number of patients with at least one COPD exacerbation leading to hospitalisation during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with at least one moderate to severe COPD exacerbation leading to hospitalisation is presented.</description>
        <time_frame>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</time_frame>
        <population>Treated set (TS) -This patient set includes all randomised patients who were documented to have taken at least 1 dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 Microgram (μg)</title>
            <description>Patient received 5 μg Tiotropium inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (5 μg) + Olodaterol (5 μg)</title>
            <description>Patient received 5 μg Tiotropium + 5 μg Olodaterol fixed-dose combination (FDC) inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One COPD Exacerbation Leading to Hospitalisation During the Actual Treatment Period.</title>
          <description>Number of patients with at least one COPD exacerbation leading to hospitalisation during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with at least one moderate to severe COPD exacerbation leading to hospitalisation is presented.</description>
          <population>Treated set (TS) -This patient set includes all randomised patients who were documented to have taken at least 1 dose of trial medication.</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3941"/>
                <count group_id="O2" value="3939"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="469"/>
                    <measurement group_id="O2" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cox’s proportional hazard model was used to estimate the hazard ratio and the corresponding Confidence Interval. A log-rank test was used to obtain the p-value</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2773</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>Tiotropium (5 μg) + Olodaterol (5 μg) versus Tiotropium (5 μg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With All-cause Mortality Occurring During the Actual Treatment Period.</title>
        <description>Number of patients with all-cause mortality occurring during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with all-cause mortality is presented.</description>
        <time_frame>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</time_frame>
        <population>Treated set (TS) -This patient set includes all randomised patients who were documented to have taken at least 1 dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 Microgram (μg)</title>
            <description>Patient received 5 μg Tiotropium inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (5 μg) + Olodaterol (5 μg)</title>
            <description>Patient received 5 μg Tiotropium + 5 μg Olodaterol fixed-dose combination (FDC) inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With All-cause Mortality Occurring During the Actual Treatment Period.</title>
          <description>Number of patients with all-cause mortality occurring during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with all-cause mortality is presented.</description>
          <population>Treated set (TS) -This patient set includes all randomised patients who were documented to have taken at least 1 dose of trial medication.</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3941"/>
                <count group_id="O2" value="3939"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cox’s proportional hazard model was used to estimate the hazard ratio and the corresponding Confidence Interval. A log-rank test was used to obtain the p-value</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7357</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
            <estimate_desc>Tiotropium (5 μg) + Olodaterol (5 μg) versus Tiotropium (5 μg)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of trial medication until 21 days after last in-take of trial medication, up to 381 days</time_frame>
      <desc>Safety analyses were based on the treated set, which included all randomised patients who took at least 1 dose of trial medication during the randomised treatment period. Patients were only actively requested to report adverse events during the on-treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tiotropium 5 Microgram (μg)</title>
          <description>Patient received 5 μg Tiotropium inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium (5 μg) + Olodaterol (5 μg)</title>
          <description>Patient received 5 μg Tiotropium + 5 μg Olodaterol fixed-dose combination (FDC) inhalation solution – RESPIMAT inhaler once daily orally for 360 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="862" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="810" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated idioventricular rhythm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Aortic valve disease mixed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cor pulmonale acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cor pulmonale chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Myocardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Myocardial bridging</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Porokeratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Retinal anomaly congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Syringomyelia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Gaze palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Necrotising colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Oesophagitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Medical device site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Medical device site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Botulism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Colon gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Infective glossitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Intestinal gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Oral bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Septic arthritis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Strongyloidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Anastomotic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Nail injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Occupational exposure to product</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Peripheral arterial reocclusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Petroleum distillate poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Suture rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Urethral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Urinary retention postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Vascular procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Breath sounds absent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>PCO2 increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Electrolyte depletion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cartilage hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Sarcopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bone neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cerebellopontine angle tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Ear neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lung infiltration malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Metastases to adrenals</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Metastatic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Mucoepidermoid carcinoma of salivary gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Oesophageal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Oral haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Papillary renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Penis carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pharyngeal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Renal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Vocal cord neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acoustic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Alcohol induced persisting dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Anterior interosseous syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Facial neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hemianaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hemianopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Mononeuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Quadriplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Device lead damage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Brief psychotic disorder with marked stressors</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Renal salt-wasting syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Urethral fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Alveolitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bronchial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="405" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="394" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Non-cardiogenic pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Reflux laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Enterostomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Gallbladder operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Lung transplant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Pancreatic operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Brachiocephalic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Macroangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Microscopic polyangiitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Subclavian artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Subgaleal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Thromboangiitis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1786" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1770" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="293" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="281" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1504" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="1519" subjects_at_risk="3939"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="232" subjects_at_risk="3941"/>
                <counts group_id="E2" subjects_affected="203" subjects_at_risk="3939"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One site was closed for cause due to data irregularities. The data from the 21 patients at this site were excluded from the patient sets used for analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

